The US Food and Drug Administration last week said it would not consider a new flu vaccine for public distribution. But a few days later, it changed course. Is that reversal part of a larger change in the Trump administration’s efforts to ‘Make America Healthy Again’? The FT’s US Pharmaceuticals Correspondent Patrick Temple-West and US Managing Editor Brooke Masters explain. Plus, the FT’s James Politi decodes the Supreme Court’s decision on Trump’s sweeping tariffs.

Mentioned in this podcast:

Trump administration reverses move to block Moderna flu vaccine trial

White House launches TrumpRx as drug companies warn of sales hit

Swamp Notes is hosted by Marc Filippino and produced by Henry Larson. We had help this week from Lauren Fedor and Maneula Saragosa. This week’s show was mixed by Sam Giovinco. Special thanks to Pierre Nicholson. Our executive producer is Topher Forhecz and the FT’s global head of audio is Cheryl Brumley.

The FT does not use generative AI to voice its podcasts.

CREDIT: MS NOW, CNN, Forbes, @SecKennedy on X, Associated Press

Read a transcript of this episode on FT.com

Hosted on Acast. See acast.com/privacy for more information.

Maha’s big reversal and a Scotus decision on tariffs